Clinical Trials

Clinical Trials

The mission of our clinical trials is to provide patients in Northern Nevada with kidney and endocrine-associated conditions access to the most advanced and cutting-edge treatments and technologies for their conditions.

Sierra Nevada Speciality Care is actively involved in many clinical research trials. We focus on clinical trials that are attempting to improve the care of chronic kidney disease, hypertension, genetic renal disease, gout, anemia, electrolyte abnormalities, and a variety of other conditions associated with kidney care. We believe any, and all, patients with advanced chronic diseases, should have access to the most recent and advanced care strategies and medications available.

Our team of dedicated research nurses and physicians have many years of experience caring for and monitoring patients in clinical trials. We work in concert with local labs and imaging centers to administer the trials, limiting the burden of travel and inconvenience.

If you feel you may be a good fit for one of the trials below, please let your care providers know.

Active Studies

Active: Not Enrolling

Name: Duplex Study-Travere
Title: To assess the safety and tolerability of sparsentan and to determine the long-term nephroprotective potential of treatment with sparsentan compared to an angiotensin receptor blocker in patients with primary focal segmental glomerulosclerosis (FSGS).
Trial Information: Click for details
Name: Protect-Travere
Title: To assess the safety and tolerability of sparsentan and to determine the effect of sparsentan on proteinuria and renal function, as compared to angiotensin receptor blocker, in patients with Immunoglobulin A Nephropathy (IgAN).
Trial Information: Click for details.

Active: Currently Screening

Name: Calciphyx-Sanifit Therapeutics S.A.
Title: To Assess the Efficacy and Safety of SNF472 When Added to Background Care for the Treatment of Calciphylaxis.
Trial Information: Click for details.

Name: Redukx-Ardelyx
Title: A two-part proof-of-concept phase 2 study: An open-label, dose-ranging phase (Part A) followed by a randomized, single-blind, placebo-controlled phase (Part B) evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia.
Trial Information: Click for details.

Name: GFB-887-201-Goldfinch
Title: An Interventional study: A Phase 1/2a Placebo-Controlled Study to Evaluate the study drug in Patients with Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease.
Trial Information: Click for details.

Name: Focus-Akebia Therapeutics
Title: A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion from a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects.
Trial Information: Click for details.